A diet based on multiple functional concepts improves cardiometabolic risk parameters in healthy subjects by Tovar, Juscelino et al.
RESEARCH Open Access
A diet based on multiple functional concepts
improves cardiometabolic risk parameters in
healthy subjects
Juscelino Tovar
1*, Anne Nilsson
2, Maria Johansson
1, Rickard Ekesbo
3, Ann-Margreth Åberg
3, Ulla Johansson
4 and
Inger Björck
1,2
Abstract
Background: Different foods can modulate cardiometabolic risk factors in persons already affected by metabolic
alterations. The objective of this study was to assess, in healthy overweight individuals, the impact of a diet
combining multiple functional concepts on risk markers associated with cardiometabolic diseases (CMD).
Methods: Fourty-four healthy women and men (50-73 y.o, BMI 25-33, fasting glycemia ≤ 6.1 mmol/L) participated
in a randomized crossover intervention comparing a multifunctional (active) diet (AD) with a control diet (CD)
devoid of the “active” components. Each diet was consumed during 4 wk with a 4 wk washout period. AD
included the following functional concepts: low glycemic impact meals, antioxidant-rich foods, oily fish as source
of long-chain omega-3 fatty acids, viscous dietary fibers, soybean and whole barley kernel products, almonds,
stanols and a probiotic strain (Lactobacillus plantarum Heal19/DSM15313).
Results: Although the aim was to improve metabolic markers without promoting body weight loss, minor weight
reductions were observed with both diets (0.9-1.8 ± 0.2%; P < 0.05). CD did not modify the metabolic variables
measured. AD promoted significant changes in total serum cholesterol (-26 ± 1% vs baseline; P < 0.0001), LDL-
cholesterol (-34 ± 1%; P < 0.0001), triglycerides (-19 ± 3%; P = 0.0056), LDL/HDL (-27 ± 2%; P < 0.0001), apoB/
apoA1 (-10 ± 2%; P < 0.0001), HbA1c (-2 ± 0.4%; P = 0.0013), hs-CRP (-29 ± 9%; P = 0.0497) and systolic blood
pressure (-8 ± 1%¸ P = 0.0123). The differences remained significant after adjustment for weight change. After AD,
the Framingham cardiovascular risk estimate was 30 ± 4% (P < 0.0001) lower and the Reynolds cardiovascular risk
score, which considers CRP values, decreased by 35 ± 3% (P < 0.0001).
Conclusion: The improved biomarker levels recorded in healthy individuals following the multifunctional regime
suggest preventive potential of this dietary approach against CMD.
Keywords: Cardiometabolic disease, metabolic syndrome, dietary prevention, functional foods, randomized con-
trolled trial, crossover design
Background
Cardiometabolic diseases (CMD), i.e. cardiovascular dis-
ease and diabetes mellitus, are important causes of mor-
bidity and mortality worldwide [1]. Therefore, any
person with multiple cardiometabolic risk factors would
benefit from lifestyle changes, including improvement of
dietary habits, to favorably modify as many as possible
risk-associated features [2]. Current recommendations
for dietary management of subjects with high metabolic
risk involve quantitative and qualitative changes in fat
and sugar intakes and high consumption of fruits, vege-
tables, and whole grains [3]. These guidelines focus on
lowering LDL cholesterol, fasting glycemia, body weight
and blood pressure as a way to reduce the risk of heart
disease [2,3]. In this context, a portfolio of vegetarian
foods has been shown capable of improving LDL choles-
terol, HDL cholesterol and CRP values in hypercholes-
terolemic subjects [4-7]. Similarly, a Nordic-type diet
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lemics [8].
However, a more comprehensive approach to the diet-
ary prevention of CMD also requires attention to other
risk factors besides altered blood lipids or glycemia. An
increasing number of studies show that different func-
tional foods and ingredients [9,10] may exert positive
effects on particular parameters related to the metabolic
syndrome (MetS), a cluster of pathophysiologic condi-
tions increasing cardiometabolic risk [11-13]. Such
observations may provide the basis for an effective pre-
ventive dietary strategy, in which the inclusion of an
ample spectrum of active food components or properties
may decrease multiple risk factors. The present investi-
gation explores the CMD preventive potential of a diet
based on a combination of functional concepts, chosen
on the basis of their beneficial effects on single meta-
bolic risk markers.
Since subclinical chronic inflammation is considered
an important factor in the etiology of CMD and MetS
[2,12,13], the components of the multifunctional “active”
diet (AD) were selected mainly for their perceived abil-
ities to reduce inflammatory tonus. Within this frame,
AD included low glycemic impact foods/meals, foods
naturally rich in antioxidant polyphenols and fish pro-
ducts rich in omega-3 fatty acids [14-17]. Moreover, the
active diet also contained a probiotic Lactobacillus strain
capable to decrease the inflammatory response in an
animal model [18] and an important supply of soluble
dietary fiber from barley and oat, with suggested prebio-
tic antiinflammatory action in humans [19-21]. Another
functional concept encompassed in the diet corresponds
to foods and ingredients with recognized blood lipid-
modulating actions, cholesterol lowering items in parti-
cular [2,4].
We hypothesized that a combination of the above
food concepts may target sub-clinical inflammation in a
synergistic way and thus allow for the prescription of
practically feasible intakes of the active foods. The study
was performed in a healthy middle-aged group of over-
weight volunteers, comparing the AD vs. a control diet
(CD) using a cross-over design, with 4-wk study periods.
The aim was to improve cardiometabolic risk-associated
parameters by changing dietary composition without
promoting weight loss.
Participants and methods
Participants
Volunteers without any known medical condition (36
females, 8 men) were recruited through advertisement
in local newspapers and were informed orally and in
writing of the project disposal, emphasizing the non
weight-loss character of the investigation. Inclusion cri-
teria were age between 50 and 73, body mass index in
the 25-33 kg/m
2 range and fasting plasma glucose value
≤ 6.1 mmol/L. Only medications accepted were hor-
mone replacement for thyroid problems (if constant
during the whole trial; 1 female subject) and prescrip-
tion-free painkillers without antinflammatory action.
B a s e l i n ed a t ac o l l e c t e da tt h et i m eo ft h ef i r s tc l i n i c a l
visit are shown in Table 1.
Study Protocol
T h es t u d yw a sd e s i g n e da sar a n d o m i z e d ,c o n t r o l l e d ,
crossover trial of the effect of a multifunctional AD on
markers related to cardiometabolic risk. Participants
were randomly assigned to one of two treatment orders
starting with the AD or the CD, respectively. Each diet
phase lasted 4 wk with a 4-wk washout period. The
whole trial included four clinical visits, one before and
one after each intervention period. During the first visit
the participants underwent a physical examination,
including auscultation of heart and lungs.
On each clinical visit, fasting body weight was
recorded and BP was measured twice, while seating, in
the non-dominant arm with a mercury
Table 1 Characteristics of participants at baseline
a
Whole group
(n = 44)
Females
(n = 36)
b
Males
(n = 8)
Age (y) 63.3 ± 0.8 63.2 ± 0.8 63.6 ± 1.9
Body weight (kg) 79.4 ± 1.4 77.4 ± 1.9 88.6 ± 2.5
BMI (kg/m
2) 28.5 ± 0.3 28.5 ± 0.4 28.3 ± 0.3
Cholesterol (mmol/L)
Total 5.75 ± 0.16 5.79 ± 0.16 5.55 ± 0.25
LDL 3.65 ± 0.15 3.64 ± 0.80 3.68 ± 0.40
HDL 1.54 ± 0.05 1.62 ± 0.06 1.20 ± 0.01
Triacylglycerols (mmol/L) 1.33 ± 0.11 1.17 ± 0.05 2.09 ± 0.20
Apolipoproteins (g/L)
Apo A-1 1.64 ± 0.03 1.68 ± 0.04 1.42 ± 0.07
Apo B 0.96 ± 0.04 0.96 ± 0.02 0.96 ± 0.11
Insulin (mU/L) 6.75 ± 0.66 6.06 ± 0.21 9.87 ± 0.01
Glucose (mmol/L) 5.20 ± 0.06 5.18 ± 0.11 5.32 ± 0.03
HOMA-IR 1.41 ± 0.15 1.25 ± 0.07 2.16 ± 0.01
HbA1c (%) 4.58 ± 0.05 4.59 ± 0.03 4.53 ± 0.05
Free fatty acids (mmol/L) 0.39 ± 0.02 0.41 ± 0.07 0.35 ± 0.05
CRP (mg/L) 2.58 ± 0.34 2.79 ± 0.22 1.61 ± 0.15
IL-6 (ng/L) 0.82 ± 0.07 0.82 ± 0.03 0.81 ± 0.13
TNF-a (ng/L) 10.51 ± 0.36 10.55 ± 0.35 10.38 ± 2.00
PAI-1 (U/mL) 24.56 ± 2.28 22.83 ± 0.31 30.63 ± 2.67
Blood Pressure (mm Hg)
Systolic 138.5 ± 2.8 139.1 ± 4.0 136.3 ± 1.2
Diastolic 80.3 ± 1.3 80.5 ± 2.0 79.8 ± 7.5
aValues are means ± SEM
b Thirty-five post-menopausal, 1 peri-menopausal.
Tovar et al. Nutrition & Metabolism 2012, 9:29
http://www.nutritionandmetabolism.com/content/9/1/29
Page 2 of 11sphyngomanometer. Venous blood was then drawn for
the assessment of fasting blood glucose, insulin, HbA1c,
cholesterol (total, LDL and HDL), triglycerides, high
sensitivity CRP (hs-CRP), PAI-1, IL-6, TNF-a,F F A ,a p o
A1, apo B.
Consumption of dietary supplements such as fish oil
(9 subjects), probiotic-containing products (11 subjects)
and herbal extracts (11 subjects), was stopped 2 weeks
before the start of the trial. Before each dietary phase,
the participants attended an introductory session with
the nutritionist, who explained practical details of the
upcoming diet period.
Volunteers were asked to maintain their normal physi-
cal activity regime during the study. A pretrial question-
naire indicated that 48% of the subjects had physical
activity equivalent to 1 h/day or more, 30% had 30-60
min/day and 22% reported a low activity level (< 30
min/day). Subjects were also instructed to record their
fasting body weight weekly. Variations larger than 1 Kg
were reported to the nutritionist, who suggested com-
pensatory dietary modifications. The intake of key com-
ponents in AD was not affected by these modifications.
Except for almonds and fresh, frozen and smoked fish,
the active food items required for the 4-wk AD were
provided. Some of the foods included in the CD were
also provided. In order to assess dietary compliance,
participants completed a daily menu checklist covering
each 4-wk diet period. They also completed a question-
naire investigating their experience with each diet.
Coaching support was provided by the nutritionist, who
contacted each participant at least once per diet period.
The study was approved by the Regional Ethical Review
Board, Lund, Sweden (Dnr 593/2008).
Diets
Participants ate their habitual diet before and between
the experimental periods. A dietary habit questionnaire
completed before randomization to the starting dietary
treatment was used to help the participants to resume
their eating habits during the washout period. To ensure
good compliance the participants were provided with a
detailed 2-wk rotating menu plan for each dietary period
(AD and CD) with all foods ingredients expressed in
weight and/or volume measures. Electronic self-taring
scales were made available whenever needed. The menu
plan also included recipes for preparing meals.
The nutritional profiles of CD and AD are shown in
Table 2. Both diets were designed in close agreement
with the Nordic Nutrition Recommendations [22] and
supplied 2,500-2,600 Kcal/d for men and 2,000-2,100
Kcal/d for women, combining foods from plant and ani-
mal origin. Both diets incorporated commercial foods
available in food stores, but the AD also included
prototypes. For a detailed list of products included in
AD see additional file 1.
AD combined several functional concepts with poten-
tial to modulate different physiological variables related
to the inflammatory tonus and cardiometabolic risk,
including:
a) food items naturally rich in antioxidants which, in
addition to the anti-inflammatory action of their antioxi-
dants [16], contain phenolics that may improve BP and
blood lipids [23-25].
b) omega-3 fatty acids, especially those long-chained
present in oily fish, which have antiinflammatory and
triglyceride-lowering properties [17,26]. In addition, the
overall fat quality was also a concept included in the
diet design. Thus, the unsaturated-to-saturated fat ratio
was larger in AD than in CD (3.6 vs 1.2, respectively;
Table 2).
c) ingredients with potential to beneficially affect the
gut microbiota: a probiotic strain (Lactobacillus plan-
tarum Heal19, DSM 15313) [18], and prebiotics, i.e.
beta-glucans and resistant starch [19,20] in intact barley
kernels, whole kernel rye flour and isolated barley fiber,
which were used for baking an experimental beta-glu-
can-rich bread. Additional sources of viscous fermenta-
ble dietary fibre were a prototype oat-based fiber drink,
a rye/oat breakfast cereal and an oat-based muesli.
d) low glycemic impact foods/meals were included for
their association with reduced risk for the MetS [27]
and Type-2 diabetes [28], and its perceived ability to
ameliorate the inflammatory tonus in healthy individuals
[29]. Low GI foods were represented by products with
high beta-glucan content which, besides their prebiotic
role, may improve glycemic regulation in a 10-h post-
ingestion perspective, through mechanisms related to
colonic fermentation and lowered inflammatory tonus
Table 2 Nutritional profile of CD and AD
Control Diet Active Diet
Women Men Women Men
Energy (kcal/day)* 2045 2570 2100 2615
Protein (E%) 15 14 19 18
Carbohydrate (E%) 56 55 51 50
Fat (E%) 29 30 31 31
Saturated fat (E%) 12.8 13.2 5.9 5.9
Monounsaturated fat (E%) 10.5 11.1 13.0 13.6
Polyunsaturated fat (E%) 3.6 3.7 8.2 8.4
ω-6 fatty acids (E%) 2.9 3.1 4.2 4.3
ω-3 fatty acids (E%) 0.8 0.8 2.2 2.3
ω-6/ω-3 ratio 3.8 3.8 1.9 1.9
Dietary fiber (g/day) 22 26 49 61
Cholesterol (mg/day) 200 240 140 160
* Increased energy intake was prescribed for subjects that experienced weight
loss during the initial weeks (see Study Protocol section)
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baked from a wheat flour/guar gum blend: This item
promotes a low glycemic response, with reduced peak
and prolonged duration of net increment above fasting
glucose levels (A. Nilsson, K. Radeborg et al., unpub-
lished results). Additionally, AD included ingredients
that lower the post-meal glycemic excursion, such as
whey protein and vinegar [14,15].
e) ingredients with acknowledged abilities to normal-
ize blood levels of both total and LDL cholesterol were
also provided: different soybean products, a margarine
enriched in stanol esters and dry almonds [4,12,30-32].
The mean daily quantities of the different functional
ingredients in AD and the main functional properties
considered for their selection are summarized in Table
3. None of the active ingredients were included in the
CD, except for minor amounts of ω-3 fatty acids.
Participants were provided with a 14-day rotating
menu plan. For representative 1-day menu plans for the
CD and AD see additional file 2. A limited amount of
alcohol-containing drinks were allowed during both
dietary periods (30 and 37 g ethanol/wk for women and
men, respectively). These limits, however, did not com-
pel low-drinkers to increase their habitual alcohol con-
sumption. Due to the low overall energy contribution
from such contingent alcoholic drinks, they were not
included in the estimation of the energy content of
diets. The volunteers’ c o f f e ea n dt e ad r i n k i n gh a b i t s
were not modified during the trial.
Analyses
Routine blood tests were analyzed at the Clinical Chem-
istry Laboratory/Skåne University Hospital Lund, on
fasting plasma (total and HDL cholesterol, triacylglycer-
ols, apo A-1, apo B, high-sensitivity C-reactive protein),
serum (insulin) or on total blood samples (HbA1c). LDL
cholesterol concentrations were calculated [39]. HOMA-
IR was calculated from fasting blood plasma-glucose
and serum insulin values [40].
Venous plasma glucose concentrations were measured
immediately after bleeding (HemoCue
®B-glucose,
HemoCueAB, Ängelholm, Sweden). Serum concentra-
tions of TNF-a and IL-6 were measured with a chemilu-
minescent immunometric assay, Immulite
®/Immulite
®
1000 TNF-a (Siemens, Deerfield, IL, USA) and a sensi-
tive enzyme-linked immunosorbent assay, Quantikine
®
HS (RD Systems Inc, Abingdon, UK), respectively. Sam-
ples with high IL-6 concentration (> 10 ng/L) in the
ELISA were also measured with the Immulite
®/Immu-
lite
®1000 IL-6 assay (Siemens, Deerfield, IL, USA).
Serum FFA were assessed with an enzymatic colori-
metric assay kit (Wako Chemicals GmbH, Germany).
Plasminogen activator inhibitor (PAI-1) activity in
plasma was measured with TriniLize PAI-1 Activity kit
(Trinity Biotech, Jamestown NJ, USA).
The diet compositions were analyzed using the 2009
food database from the Swedish National Food Adminis-
tration and a computerized calculation program (Dietist
XP 3.1; Kost och Näringsdata AB, Bromma, Sweden).
Table 3 Proposed functional action, previously tested dose and actual average content of active components in the
active diet
Main functional
role
Previously tested dose (g/
day)
References Content in the AD
(g/day)
Women Men
Soybean/soy protein Cholesterol-lowering, anti-inflammatory 25-47 [4,30,33-35] 21 25
Viscous fibers Cholesterol- lowering, prebiotic, GI-
reducing
10-25 [12,19]
b-glucans 5.8 6.2
Guar gum 5.6 6.7
Total 11.4 12.9
Long chain ω-3 fatty acids (20:5 +
22:6)
Triglyceride-lowering, anti-inflammatory 2-6 [17,26] 2.4 3.0
Almonds Cholesterol-lowering 28-100 [4,32] 28 28
Plant stanols Cholesterol-lowering 2-3 [4,31] 2.0 2.7
Cinnamon Antioxidant 6 [25] 3.0 3.0
Blueberries Antioxidant, prebiotic 350 [36] 74.5 94.5
Vinegar GI -reducing 20 [14] 22.5 22.5
Probiotic Cholesterol-lowering, anti-inflammatory 10
10 CFU [18,37,38] 0.1
(10
10
CFU)
0.1
(10
10
CFU)
Whey protein* GI-reducing 10 [15] 4.3 4.3
*Whey protein (10 g) was only consumed simultaneously with high glycemic index meals (potatoes, parsnip), 3 times per week.
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The results are expressed as means ± SEM. Data were
evaluated by mixed model ANOVA with sequence and
interaction between diet and start/end of treatment peri-
ods as fixed effects, and participants within sequence
and visit as random effects. Least square means were
estimated for the start (Active-week 0, Control-week 0)
and end values (Active-wk 4, Control-wk 4) for each
diet. Least square means and confidence intervals were
calculated for the differences between Active/wk 0, Con-
trol/wk 0, Active/wk 4 and Control/wk 4, as well as for
the net difference between the diets, i.e. (Active/wk 4 -
Active/wk 0) - (Control/wk 4 - Control/wk 0). Another
set of analyses with body weight included as a continu-
ous covariate was performed. Analyses were carried out
using SAS PROC Mixed (v. 8.2, SAS Institute Inc., Cary,
NC, USA). Ten-year coronary heart disease risk was cal-
culated both with the Framingham Study equation [41]
considering age, gender, total cholesterol, HDL-choles-
terol, smoking and systolic BP values, and the Reynolds
Risk Score [42,43], which also incorporates CRP values.
Power calculation
Primary outcome measure was change in plasma LDL
cholesterol. Assuming a 0.5 mmol/L (approximately
10%) post-diet difference and a 0.97 SD [44], with a =
0.05 and 1-b = 0.8, a minimum of 30 participants were
required. Among additional measures, changes in hs-
CRP were also taken into account. Assuming a 0.44 mg/
L (10%) post-diet difference and a SD of 1.0 [45], the
required sample size was 42 subjects. Data obtained
from hypercholesterolemics with normal CRP levels [7]
confirmed that this n value provides sufficient power for
assessing CRP changes.
Results
Study population and dietary compliance
Recruitment began February 2009. Trials took place
between March 2009 and February 2010. Forty-six
volunteers enrolled in the study. The volunteers came
from different towns and rural areas in Southwestern
Sweden. One participant dropped out during the first
week. Forty-five completed the two phases of the inter-
vention. One completer declared to have suffered a
minor cerebro-vascular incident some years ago and was
therefore excluded from the evaluation. Results from 44
completers (36 women and 8 men) aged 51 - 73 (mean
63.3) were analysed. Only 2 subjects were smokers.
Baseline data confirmed the healthy condition of the
cohort studied. This was also evident from the fact that
26 out of the 44 completers (i.e. 59%) showed none of
the MetS features assessed (total cholesterol > 150 mg/
dL, BP > 130/85 mm Hg and HDL-cholesterol < 50 mg/
dL) [46].
Adherence to the dietary plan was good, with similar
compliance (P = 0.07) for AD (92 ± 2%) and CD (89 ±
5%). No major problem to consume the prescribed foods
was reported. Fifty percent of the participants described
AD as more satiating than their habitual diet and 25%
expressed that sensation for CD. Ninety percent of the
participants experienced increased intestinal gas produc-
tion with AD as compared to their regular regimes; how-
ever, only five participants (11%) qualified this as a burden.
Body weight
Despite the dietary advice provided, weight losses were
registered after CD (-0.9%) and AD (-1.8%) (Table 4).
Although final body weight was similar with the two
treatments, there was a significant difference between
diets (P = 0.0113) (Table 4).
Blood lipids and lipoproteins
AD reduced total cholesterol (P < 0.0001), LDL choles-
terol (P < 0.0001) and triglycerides (P = 0.0004) by 26%,
24% and 19%, respectively, while no change was
recorded after the CD period (Table 4). The difference
between the two dietary treatments remained after cor-
rection for body weight reduction (P < 0.0001, P <
0.0001 and P = 0.0011, respectively; Table 4).
HDL-cholesterol values were similarly reduced by both
diets (P = 0.01635) but AD improved both the LDL/
HDL ratio (from 2.51 to 1.83, ie. -27%, P < 0.0001) and
ApoB to ApoA-1 ratio (from 0.59 to 0.53; -10%; P <
0.0001). The difference between diets was significant (P
< 0.0001) after correction for weight changes (Table 4).
Glycemic control variables
No difference in the effect on fasting insulin concentra-
tions was recorded between AD and CD (P = 0.9410),
although AD promoted a significant (P = 0.0436) reduc-
tion from baseline (Table 4). AD increased fasting blood
glucose levels by 6%, with a significant difference between
diets after correction for weight changes (P = 0.0002;
Table 4). None of the diets affected HOMA-IR values or
fasting FFA levels. A 2% decrease in HbA1c was detected
after AD, an effect that remained significant after correc-
tion for body weight variation (P = 0.0013; Table 4).
Blood pressure
Systolic BP was 8% lower after AD whereas CD had no
effect. The difference between diets remained significant
after weight correction (P = 0.0134; Table 4). Diastolic
pressure values were not affected by any of the diets
(Table 4).
Inflammatory and pro-thrombotic status markers
AD reduced hs-CRP value by 29%, with no effect for CD
(Table 5). The difference between diets was significant
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In spite of a 26% drop in PAI-1 after AD, no net differ-
ence was registered between the two diets (P = 0.3854).
None of the diets affected fasting IL-6 or TNF-a
concentrations.
Cardiovascular risk
Significantly lower overall cardiovascular risk scores
were calculated after AD (Table 6). The Framingham
Study algorithm indicated a 30-percent risk drop (P <
0.0001). The Reynolds risk score predicted a larger risk
decline (35%; P < 0.0001). The CD did not reduce risk
estimates. The reduction in risk estimates with AD
remained significant after weight correction.
Discussion
This investigation looked at the possibility of modulat-
ing diverse cardiometabolic risk factors by a diet based
on multiple functional food concepts. Although a num-
ber of therapy-oriented dietary studies have been
Table 4 Effect of CD and AD on plasma lipids, parameters of insulin sensitivity and blood pressure
a
Control Diet Active Diet
Week 0 Week 4 Change (%) Week 0 Week 4 Change (%) P (A-C)
b P (A-C; weight corrected)
c
Body weight (kg)
d 78.9 ± 1.7 78.2 ± 1.34
h -0.9 79.4 ± 1.36
i 78.0 ± 1.30
f -1.8 0.0113
Cholesterol (mmol/L)
Total
d 5.73 ± 0.16 5.79 ± 1.39 1 5.81 ± 0.17 4.29 ± 0.10
f -26 < 0.0001 < 0.0001
LDL
d 3.66 ± 0.15 3.70 ± 0.16 1 3.65 ± 0.16 2.42 ± 0.10
f -34 < 0.0001 < 0.0001
HDL
e 1.53 ± 0.04 1.43 ± 0.04
h -7 1.54 ± 0.05 1.39 ± 0.04
g -10 0.1637 0.1501
Triglycerides (mmol/L)
d 1.36 ± 0.11 1.38 ± 0.62 1 1.32 ± 0.09 1.07 ± 0.06
g -19 0.0056 0.0011
Apolipoproteins (g/L)
Apo A-1
d 1.62 ± 0.03 1.54 ± 0.03
f 5 1.62 ± 0.04 1.40 ± 0.02
f -14 < 0.0001 < 0.0001
Apo B
d 0.95 ± 0.04 0.95 ± 0.03 0 0.94 ± 0.04 0.72 ± 0.02
f -23 < 0.0001 < 0.0001
Ratios
LDL/HDL
d 2.53 ± 0.03 2.73 ± 0.03
h 8 2.51 ± 0.02 1.83 ± 0.03
f -27 < 0.0001 < 0.0001
ApoB/ApoA-1
d 0.60 ± 0.03 0.63 ± 0.03 5 0.59 ± 0.03 0.53 ± 0.02
f -10 < 0.0001 < 0.0001
Insulin (mU/L)
e 6.70 ± 0.42 5.70 ± 0.25 -14 6.08 ± 0.42 5.03 ± 0.36
h -17 0.9410 0.9826
Glucose (mmol/L)
d 5.21 ± 0.07 5.13 ± 0.07 -1 5.17 ± 0.07 5.46 ± 0.08
g 6 0.0002 0.0002
HOMA-IR 1.39 ± 0.08 1.17 ± 0.08 -16 1.26 ± 0.09 1.09 ± 0.06 -14 0.7376 0.6983
HbA1c (%)
d 4.56 ± 0.05 4.58 ± 0.05 1 4.55 ± 0.05 4.47 ± 0.05
h -2 0.0007 0.0013
Free fatty acids (mmol/L) 0.37 ± 0.02 0.37 ± 0.02 0 0.37 ± 0.02 0.37 ± 0.03 0 0.9673 0.9627
Blood pressure (mm Hg)
Systolic
e 135 ± 2 132 ± 2 -2 136 ± 2 128 ± 2
f -8 0.0123 0.0134
Diastolic 79 ± 1 76 ± 1 -4 79 ± 1 76 ± 1 -4 0.9984 0.9265
a Values are means ± SEM. To convert cholesterol and triglyceride values to mg/dL, multiply by 38.67 and 88.57, respectively. To convert apo A-1 and apo B
values to mg/dL, multiply by 100.
bP value for the comparison of changes after Active diet and Control diet.
cP value for the comparison of changes after Active diet and Control diet, after correction for weight change
d, e The overall effect of diet was significant:
dP < 0.001,
eP < 0.05.
f, g, h Significantly different from baseline (Week 0):
fP < 0.0001,
gP < 0.001,
hP < 0.05.
iActive diet baseline (Week 0) significantly different from control diet baseline, P < 0.05.
Table 5 Effect of CD and AD on circulating inflammatory and thrombotic markers
a
Control Diet Active Diet
Week 0 Week 4 Change (%) Week 0 Week 4 Change (%) P (A-C)
b P (A-C; weight corrected)
c
CRP (mg/L) 2.59 ± 0.34 2.89 ± 0.42 12 2.79 ± 0.39 1.99 ± 0.27
e -29 0.0446 0.0497
IL-6 (ng/L) 0.96 ± 0.09 0.93 ± 0.09 -3 0.71 ± 0.05
d 0.81 ± 0.09 14 0.6232 0.3807
TNF-a (ng/L) 9.95 ± 0.36 10.09 ± 0.45 1 11.04 ± 0.46
d 10.38 ± 0.42 -6 0.0971 0.1094
PAI-1 (U/mL) 23.34 ± 1.69 19.33 ± 1.68 -19 23.70 ± 2.17 17.65 ± 1.47
e -26 0.3854 0.4104
aValues are expressed as means ± SEM.
bP value for the comparison of changes after Active diet and Control diet.
cP value for the comparison of changes after Active diet and Control diet, after correction for weight change
dActive diet baseline (Week 0) significantly different from control diet baseline, P < 0.05.
eSignificantly different from baseline (Week 0), P < 0.05.
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mized intervention has examined the potential CMD
preventive power of a complex functional food array tar-
geting subclinical inflammation. Present results put for-
ward interesting possibilities for this dietary approach.
One characteristic of this study is the healthy condi-
tion of the cohort evaluated. The volunteers had no par-
ticular diagnosis, beyond being considered at risk for
cardiometabolic alterations due to their age (63.3 ± 0.8
y) and BMI (28.5 ± 0.3 kg/m
2). According to mean base-
line values for blood lipids, BP and glucose homeostasis
parameters (Table 1), the group represents the healthy
segment of the Swedish population in the 50-75 year-
old range. This judgment is supported by the fact that
59% of the volunteers exhibited none of the MetS fea-
tures evaluated, which contrasts with data from a recent
survey of MetS prevalence among 50-60 year olders liv-
ing in Gothenburg, showing that only 5% of this popula-
tion group has no risk factor associated to the syndrome
[48].
The AD evaluated here included a cluster of func-
tional concepts selected for their abilities to influence
different CMD-associated factors, with emphasis on
anti-inflammatory properties. The efficacy of the indivi-
dual concepts has been documented at various levels
including intervention studies with humans. Further-
more, since the concepts influence different aspects of
the pathophysiological processes associated with CMD,
synergistic interaction between functional agents may
occur and facilitate the overall modulation of multiple
risk indicators. Thus, the daily dosage of some func-
tional components was set below the amount required
for optimal effect when tested separately (Table 3),
improving the general palatability of the diet.
CD exhibited a good nutritional profile, which
matched the Nordic Nutritional Recommendations.
Although its dietary fiber content was lower, the CD
contribution approached the current estimated fiber
intake for the Swedish population (Swedish Food
Administration, Personal Communication). Also, besides
being rich in functional ingredients, AD had an
improved fat quality (Table 2) and its long-chain ω-3
fatty acid content was 10 times larger than in CD. Both
diets were well accepted and tolerated by the partici-
pants. The variety of foods encompassed, the inclusion
of meat and other animal products and the minor
amount of alcoholic drinks allowed favored the high
dietary adherence and completion rates recorded.
A somewhat greater weight loss was observed after
AD, which agrees with the marked satiating action
reported for this diet by most participants, an effect that
may be due to its higher dietary fiber and protein con-
tents. In fact, 50% of the participants were prescribed
increased dietary energy after the first 2 weeks on the
regime when their weight loss tendency became evident,
in contrast to only 25% requiring that intervention dur-
ing the CD period. In spite of that a 1.8% (1.4 ± 0.2 kg)
mean decrease was recorded after AD. Nonetheless, the
statistical adjustment made for the impact of weight var-
iation showed that most of the metabolic improvement
observed after AD was attributable to the dietary modi-
fication per se and not to a mere weight loss effect.
Blood lipid and apolipoprotein profiles were practically
unaffected by CD but sharp reductions in triglycerides,
total cholesterol, LDL cholesterol as well as in LDL/
HDL and apoB/apoA1 ratios were recorded after the
AD period. The latter observation is noteworthy, given
the strong association between this quotient and the
MetS [49]. The beneficial impact of a low glycemic
index diet on blood cholesterol [50] together with the
triglyceride-reducing action of polyunsaturated fatty
acids from marine origin [10] and content of other
known cholesterol-lowering foods and ingredients (soy-
beans and soy protein, viscous dietary fibers, plant sta-
nols and almonds) are most probably responsible for the
overall effect observed with AD.
None of the diets affected insulin sensitivity as esti-
mated by HOMA-IR, although AD promoted slightly
higher fasting glucose values than CD. Such an
increased glycemia should not pose a risk for healthy
Table 6 Effect of CD and AD on 10-y cardiovascular risk
a
Control Diet Active Diet P (A-C)
b P (A-C; weight corrected)
c
Calculated 10-y CHD risk (%) Week 0 Week 4 Change (%) Week 0 Week 4 Change (%)
Framingham equation
d, f 5.0 ± 0.8 5.2 ± 0.8 4 5.2 ± 0.8 3.6 ± 0.6
e -30 < 0.0001 0.0002
Reynolds score
d, g 6.2 ± 0.8 6.2 ± 0.8 1 6.3 ± 0.9 4.1 ± 0.6
e -35 < 0.0001 < 0.0001
a Values are means ± SEM.
bP value for the comparison of changes after Active diet and Control diet.
cP value for the comparison of changes after Active diet and Control diet, after correction for weight change.
d The overall effect of diet was significant: P < 0.0001.
e Significantly different from baseline (Week 0), P < 0.0001.
f CHD risk calculated using the Framingham cardiovascular disease predictive equation [41] considering gender, age, total cholesterol, HDL-cholesterol, and
smoking habits.
g CHD risk calculated using the Reynolds risk score [42,43] considering gender, age, total cholesterol, HDL-cholesterol, CRP and smoking habits.
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recorded in HbA1c and unchanged values for fasting
FFA.
T h em i n o rd e c r e a s ei nH b A 1-c observed with AD
might be the consequence of modulated glycation rate
during the AD period. The diet’s low glycemic impact
and high phenolic content, both with anti-glycative
effects [51,52], may have contributed to this result.
CRP is an indicator of the inflammatory status of
recognized importance in relation to cardiometabolic
alterations [42,53], with independent predictive value for
incident diabetes and cardiovascular diseases [7,54]. The
biomarker decreased markedly after AD, with significant
difference between diets after adjustment for weight
change. It is tempting to speculate that the improved
CRP levels may be due to the antinflammatory proper-
ties of AD. The CRP-lowering effectivity of a diet
enriched in oily fish, blueberries and wholegrain pro-
ducts was recently shown in patients with impaired glu-
cose tolerance [55].
In addition to improving metabolic risk indicators, AD
promoted a significant drop in systolic BP. Such a
change may be related, for instance, to the high supply
of long chain ω-3 fatty acids, ingredients with suggested
BP-modulating activity [56]. Although the present
cohort was normotensive (Table 1), the observed pres-
sure reduction resembles that observed with a compo-
site drug treatment in hypertensive volunteers [57].
Besides modulating individual markers associated to
CMD, AD also decreased cardiovascular risk as esti-
mated by two different models. The Reynolds algorithm
resulted in larger variation from baseline (-34%) than
the Framingham score (-30%), stressing the importance
of the CRP reduction promoted by this diet.
The improvement achieved for different biomarkers
after AD in this relatively low risk group, compares favor-
ably with other dietary interventions. Most of the investi-
gations on the effect of diet CMD-related parameters
have been carried out in patients that have metabolic
alterations, such as dyslipidemia. A portfolio of choles-
terol-lowering foods reduced LDL cholesterol values by
33% in a 4-week trial with hypercholesterolemics [5],
which is alike the variation recorded here with a normo-
cholesterolemic group. Furthermore, the presently
reported impact of AD on the apoB/Apo A1 ratio, CRP
concentration and Framinghams CVD risk is comparable
to those previously attained in hypercholesterolemics fol-
lowing the cholesterol-lowering portfolio regime [5,6].
Also, the effect of AD on total (-26%) and LDL cho-
lesterol levels (-34%) exceeds those reported for the
“Nordic” diet in hypercholesterolemic individuals (-16%
and -21%, respectively) a regime that, in contrast to
ours, did not affect triglycerides or systolic BP beyond
weight-loss effects [8]. The AD also promoted greater
LDL-cholesterol, triglyceride and CRP reductions than
Mediterranean-style regimes administered to individuals
at high cardiovascular risk [58].
Compared to other dietary interventions performed in
healthy volunteers, the action of the AD on different
CMD-related variables is also remarkable. Its effects on
systolic BP are similar to those of reduced sodium/
DASH [59] or whole-grain [60] regimes. Moreover, in
terms of LDL cholesterol reduction AD appears
impressively more effective than vegetarian [61] or low
GI [50] regimes. The larger effectiveness of AD reflects
the power of its multifunctional character.
It is relevant noting that the AD effects were observed
under conditions aiming to prevent weight changes. In
view of the perceived high satiating ability of the diet,
larger weight reductions could be expected if it was con-
sumed ad libitum. This potential deserves further inves-
tigation, since dietary interventions promoting weight
losses of 5% or more generally result in additional meta-
bolic improvement [9,62,63].
The present study had limitations. An evident con-
straint is the unbalanced gender participation, since 80%
of the participants were women. Nevertheless, the lower
responsiveness of women to treatments targeting meta-
bolic alterations, such as hyperlipidemias [64,65], stres-
ses the relevance of our results. The relative
heterogeneity of the cohort regarding metabolic charac-
teristics may also be seen as limiting. However, the
group reflects the healthy mature segment of the local
population. The study length represents another limita-
tion. Prolonged open interventions often yield inferior
results, a pattern influenced by reduced dietary compli-
ance. Nonetheless, the good acceptability recorded for
the AD allows expectations for reasonable treatment
adherence in longer term trials. An increased availability
of active food items and ingredients in the near future
may ease the achievement of this goal.
The possible impact of AD on body composition and
fat distribution was not evaluated here. Since these fac-
tors are importantly associated with cardiometabolic risk
[46,54], it would be interesting to include them in future
studies on the role of functional diets in the prevention
of cardiometabolic alterations. At last, the experimental
design envisaged sufficient statistical power regarding
changes in LDL cholesterol and CRP but the greater sta-
tistical dispersion associated to other biomarkers, such
as insulin, PAI-1 and TNF-a, may have left the study
underpowered to confirm their modification. This
should be born in mind when interpreting the non-sig-
nificant changes recorded in these parameters.
Conclusion
Tested in a group of middle-aged healthy overweight
individuals, a multifunctional diet could modulate
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bolic effects, good acceptability and ease of implementa-
tion shown for the diet in this cohort, suggest this type
of regime as a promising tool for dietary preventive
action against CMD.
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